These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16688939)

  • 1. ["Hepatitis C awareness, searching for it and referral for therapy"].
    Zeuzem S
    MMW Fortschr Med; 2006 Apr; 148(16):8. PubMed ID: 16688939
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of new hepatitis C treatments in different regions of the world.
    Wei L; Lok AS
    Gastroenterology; 2014 May; 146(5):1145-50.e1-4. PubMed ID: 24662488
    [No Abstract]   [Full Text] [Related]  

  • 4. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 5. Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Trippoli S; Fadda V; Maratea D; Messori A
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):983-4. PubMed ID: 26114910
    [No Abstract]   [Full Text] [Related]  

  • 6. HCV genotype 5: epidemiology and spread of an uncommon genotype.
    Verbeeck J; Peigue-Lafeuille H; Ross RS; Abergel A; Nevens F; Van der Merwe S; Van Ranst M; Henquell C
    J Clin Virol; 2008 Feb; 41(2):170-1. PubMed ID: 18069057
    [No Abstract]   [Full Text] [Related]  

  • 7. Tailoring antiviral therapy in hepatitis C.
    Davis GL
    Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy.
    Bonino F; Colombatto P; Civitano L; Coco B; Oliveri F; Brunetto MR
    Expert Rev Mol Diagn; 2001 Sep; 1(3):310-4. PubMed ID: 11901836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hepatitis C--the misdiagnosed epidemic. Chances for healing are available--use them!].
    Westphal K
    MMW Fortschr Med; 2006 Apr; 148(16):4-6, 8. PubMed ID: 16688938
    [No Abstract]   [Full Text] [Related]  

  • 10. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future.
    Wong JB
    Hepatology; 2002 Jul; 36(1):252-4. PubMed ID: 12085373
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapeutic options for hepatitis C.
    Waters L; Nelson M
    Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
    ; McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R
    J Gastroenterol Hepatol; 2007 May; 22(5):615-33. PubMed ID: 17444847
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver biopsy and noninvasive alternatives in relationship to the duration of antiviral treatment for hepatitis C.
    Colletta C; Smirne C; Marini C; Pirisi M
    J Clin Gastroenterol; 2008 Feb; 42(2):219-20. PubMed ID: 18209600
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult hepatitis C: how convincing are the current data?
    Welker MW; Zeuzem S
    Hepatology; 2009 Feb; 49(2):665-75. PubMed ID: 19105211
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.